| Dr David N Macleod, MD | |
|
18 Foundry St Ste 201, Concord, NH 03301-5421 | |
| (603) 228-0071 | |
| (603) 227-7535 |
| Full Name | Dr David N Macleod |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 8 Years |
| Location | 18 Foundry St Ste 201, Concord, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821544198 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 19596 (New Hampshire) | Secondary |
| 207Q00000X | Family Medicine | 19596 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Concord Regional Vna | Concord, NH | Home health agency |
| Concord Hospital | Concord, NH | Hospital |
| Franklin Regional Hospital | Franklin, NH | Hospital |
| Lakes Region General Hospital | Laconia, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Concord Hospital Inc | 6103721790 | 462 |
News Archive
When researchers at Moffitt Cancer Center and colleagues conducted a random telephone survey among blacks, whites and Hispanics in New York, Baltimore and San Juan, Puerto Rico, they found that Hispanics are nearly twice as likely to report that fear of being used as a "guinea pig" and lack of trust in medical professionals contribute in being unwilling to participate in cancer screenings.
A new Emmy Noether Independent Junior Research Group at Charité - Universitätsmedizin Berlin is studying the development of pediatric cancers. The research group is being funded by the German Research Foundation (DFG) and will receive €1.7 million over five years.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
Scientists at the University of Notre Dame have found that exposure to just 10 minutes of light at night suppresses biting and manipulates flight behavior in the Anopheles gambiae mosquito, the major vector for transmission of malaria in Africa, according to new research published in the journal Parasites and Vectors.
› Verified 4 days ago
| Entity Name | Concord Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194778571 PECOS PAC ID: 6103721790 Enrollment ID: O20040405000916 |
News Archive
When researchers at Moffitt Cancer Center and colleagues conducted a random telephone survey among blacks, whites and Hispanics in New York, Baltimore and San Juan, Puerto Rico, they found that Hispanics are nearly twice as likely to report that fear of being used as a "guinea pig" and lack of trust in medical professionals contribute in being unwilling to participate in cancer screenings.
A new Emmy Noether Independent Junior Research Group at Charité - Universitätsmedizin Berlin is studying the development of pediatric cancers. The research group is being funded by the German Research Foundation (DFG) and will receive €1.7 million over five years.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
Scientists at the University of Notre Dame have found that exposure to just 10 minutes of light at night suppresses biting and manipulates flight behavior in the Anopheles gambiae mosquito, the major vector for transmission of malaria in Africa, according to new research published in the journal Parasites and Vectors.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David N Macleod, MD 18 Foundry St Ste 201, Concord, NH 03301-5421 Ph: (603) 228-0071 | Dr David N Macleod, MD 18 Foundry St Ste 201, Concord, NH 03301-5421 Ph: (603) 228-0071 |
News Archive
When researchers at Moffitt Cancer Center and colleagues conducted a random telephone survey among blacks, whites and Hispanics in New York, Baltimore and San Juan, Puerto Rico, they found that Hispanics are nearly twice as likely to report that fear of being used as a "guinea pig" and lack of trust in medical professionals contribute in being unwilling to participate in cancer screenings.
A new Emmy Noether Independent Junior Research Group at Charité - Universitätsmedizin Berlin is studying the development of pediatric cancers. The research group is being funded by the German Research Foundation (DFG) and will receive €1.7 million over five years.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
Scientists at the University of Notre Dame have found that exposure to just 10 minutes of light at night suppresses biting and manipulates flight behavior in the Anopheles gambiae mosquito, the major vector for transmission of malaria in Africa, according to new research published in the journal Parasites and Vectors.
› Verified 4 days ago
Dr. Ana V Castellanos Mendez, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-228-7200 Fax: 603-227-7562 | |
Dr. Peter Abdalla, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-227-7000 Fax: 603-227-7191 | |
Dr. Robert Gabrielli, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-485-8441 Fax: 603-485-7718 | |
Dr. Edward G. Benoit, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 60 Commercial St, Suite 401, Concord, NH 03301 Phone: 603-228-7555 Fax: 603-227-7529 | |
Dr. Fu Sheng Wang, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-228-7000 Fax: 603-228-7307 | |
Ms. Sabrina Bolianites, ARNP Family Medicine Medicare: Medicare Enrolled Practice Location: 250 Pleasant St Fl 2, Concord, NH 03301 Phone: 603-622-6484 Fax: 603-647-8593 | |
Pralhad Shankar Bide, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 250 Pleasant St, Chfhc, Yeaple, Concord, NH 03301 Phone: 603-228-7200 Fax: 603-228-7307 |